Skip to main content

FDA Disapproves 6,500 Flavored E-cigarettes From Marketing

FDA Disapproves 6,500 Flavored E-cigarettes From Marketing

FDA Disapproves 6,500 Flavored E-cigarettes From Marketing

Introduction

Ten companies that combined produce and market roughly 6,500 flavored e-liquid and e-cigarette products were given marketing denial orders by the U.S. Food and Drug Administration (FDA).

According to the health authority, these businesses cannot promote or distribute the items in the United States, and merchants that do so run the danger of facing FDA enforcement action. FDA must provide a formal marketing order before any firm may legitimately promote a new tobacco product in the United States. However, a marketing denial order is issued if the health regulator decides it is unsafe for the general public's health.

Imperial Vapors LLC, Savage Enterprises, and Big Time Vapes are just a few of the firms the FDA cited as having gotten rejection orders. The FDA stated that it will not reveal the identities of the other two businesses, however, in order to preserve any potentially sensitive commercial information.

According to the FDA, the premarket tobacco product applications (PMTAs) filed for a range of flavor-infused e-cigarette products did not offer enough proof to support the claim that allowing their sale would be in the public's best interest.

The health regulator has prohibited tastes, including citrus, strawberry cheesecake, cool mint, and menthol. Six e-cigarette brands from Altria Group Inc.'s (MO.N) NJOY, on the other hand, have acquired full FDA clearance. 

Altria was formerly an investor in Juul, another manufacturer of e-cigarettes, but Juul is still working to have their goods approved. The FDA momentarily prohibited Juul's products last year but later put the decision on hold and agreed to review after the firm filed an appeal.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!